# A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

> **NCT03832426** · PHASE1 · COMPLETED · sponsor: **R-Pharm** · enrollment: 32 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Narlaprevir
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT03832426
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-08
- **Primary completion:** 2014-10-24
- **Final completion:** 2014-10-24
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03832426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03832426, "A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03832426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*